PCSC SEC filings, in plain English
Everything Perceptive Capital Solutions Corp has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: 8-K/A (Amendment No. 1) of FREENOME, INC. Item 2.01 (completion of acquisition or disposition of assets) supplies the financial information deferred at closing. Item 9.01(a): Freenome's unaudited condensed consolidated financial statements as of and for the six months ended June 30, 2026 and 2025 are Exhibit 99.1, and MD&A for the three and six months ended June 30, 2026 and 2025 is Exhibit 99.2. Item 9.01(b): unaudited pro forma condensed combined financial information of New Freenome as of and for the six months ended June 30, 2026 and for the year ended December 31, 2025 is Exhibit 99.3. Why it matters: Completes the Item 9.01 financial-statement obligation the de-SPAC closing triggered. Every figure sits in Exhibits 99.1-99.3 rather than in the report, so the amendment establishes that the target's accounts and the combined pro formas are now on the record without stating a single number itself. The report also notes New Freenome is a smaller reporting company and need not give market-risk disclosure.
What changed: Perceptive Capital Solutions Corp's successor Freenome, Inc. announced on July 27, 2026 that the FDA has approved SimpleScreen CRC, a blood-based colorectal cancer screening test for average-risk adults aged 45 and older, with Abbott to commercialise it in the U.S. The test detects colorectal cancer signals from cell-free DNA in blood and was evaluated in PREEMPT CRC, described as the largest prospective clinical validation study conducted for a blood-based colorectal screening test. The filing notes up to 60 million Americans remain overdue for recommended screening. Why it matters: FDA approval plus a named commercialisation partner is the single most valuable outcome available to a diagnostics de-SPAC: it converts a development-stage asset into a product with a route to market without the company having to build a sales force. Abbott taking U.S. commercialisation removes the distribution risk that usually sinks newly approved tests. The size of the underserved screening population sets the addressable market, though the filing gives no pricing, reimbursement or revenue-share terms.
What changed: Perceptive Capital Solutions Corp reported agreements around closing its business combination with Freenome Holdings. On July 20, 2026 the parties signed Amendment No. 1, cutting New Freenome's post-closing board from nine directors to seven. At closing, PCSC, the Sponsor and certain Freenome stockholders entered an Investor Rights Agreement requiring a resale registration statement within 30 calendar days of closing at the company's expense, with piggyback and underwritten demand rights. It amends and restates the IPO registration rights agreement. Why it matters: A resale registration due within 30 days of closing is the date former PCSC holders should mark: it is when sponsor shares and Freenome rollover stock become freely saleable, which is the standard source of post-deal supply pressure at a de-SPAC. Underwritten demand rights go further, letting large holders force a marketed offering. Shrinking the board from nine to seven concentrates control among fewer directors just as the company transitions from SPAC governance to operating governance.
What changed: Perceptive Capital Solutions Corp held an extraordinary general meeting on July 15, 2026 at which shareholders approved the Business Combination, Domestication, Governing Documents, Advisory Governing Documents, Nasdaq, Equity Incentive Plan and Employee Stock Purchase Plan proposals, all described in the June 17, 2026 definitive proxy statement/prospectus as supplemented on July 9, 2026. The Adjournment Proposal was not needed. Present were 5,645,461 Class A and 2,156,250 Class B ordinary shares, about 75.65% of voting power at the June 12, 2026 record date. Why it matters: This is the vote that clears the Freenome combination — every substantive proposal passed and the adjournment proposal was not required, meaning support was not marginal. Approval of the domestication moves the vehicle out of the Cayman Islands, and the Nasdaq proposal authorises the share issuance the merger requires. For holders who did not redeem, the trust of about $10.81 a share now converts into stock of the combined company rather than cash.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.